WTA
PLRX icon

Washington Trust Advisors’s Pliant Therapeutics PLRX Stock Holding History

Washington Trust Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-65
Closed -$856 – 657
2024
Q4 		$856 Hold
65
– – ﹤0.01% 640
2024
Q3 		$729 Hold
65
– – ﹤0.01% 654
2024
Q2 		$699 Hold
65
– – ﹤0.01% 654
2024
Q1 		$969 Hold
65
– – ﹤0.01% 655
2023
Q4 		$1.18K Hold
65
– – ﹤0.01% 656
2023
Q3 		$1.13K Hold
65
– – ﹤0.01% 660
2023
Q2 		$1.18K Hold
65
– – ﹤0.01% 646
2023
Q1 		$1.73K Hold
65
– – ﹤0.01% 735
2022
Q4 		$1.26K Hold
65
– – ﹤0.01% 755
2022
Q3 		$1K Buy
+65
New +$1.24K ﹤0.01% 886

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Washington Trust Advisors's PLRX Position: Q1 2025 in Review

Washington Trust Advisors sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 65 shares — an estimated $856 sold.

Washington Trust Advisors first reported a position in PLRX in Q3 2022 and held it in 10 quarters. The position peaked at $1.73K in Q1 2023. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Washington Trust Advisors reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 65 Pliant Therapeutics shares in Q1 2025, an estimated $856.
  • Washington Trust Advisors first reported a position in Pliant Therapeutics in Q3 2022 and held it in 10 quarters.
  • Washington Trust Advisors's Pliant Therapeutics position peaked at $1.73K in Q1 2023.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Washington Trust Advisors's 13F filing for Q1 2025, filed 25 Apr 2025.